These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33339442)

  • 41. The SETD8/PR-Set7 Methyltransferase Functions as a Barrier to Prevent Senescence-Associated Metabolic Remodeling.
    Tanaka H; Takebayashi SI; Sakamoto A; Igata T; Nakatsu Y; Saitoh N; Hino S; Nakao M
    Cell Rep; 2017 Feb; 18(9):2148-2161. PubMed ID: 28249161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. H4K20 monomethylation inhibition causes loss of genomic integrity in mouse preimplantation embryos.
    Shikata D; Yamamoto T; Honda S; Ikeda S; Minami N
    J Reprod Dev; 2020 Oct; 66(5):411-419. PubMed ID: 32378528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
    Sawyer BT; Qamar L; Yamamoto TM; McMellen A; Watson ZL; Richer JK; Behbakht K; Schlaepfer IR; Bitler BG
    Mol Cancer Res; 2020 Jul; 18(7):1088-1098. PubMed ID: 32198139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
    Zhang K; Wang J; Yang L; Yuan YC; Tong TR; Wu J; Yun X; Bonner M; Pangeni R; Liu Z; Yuchi T; Kim JY; Raz DJ
    Mol Cancer; 2018 Oct; 17(1):153. PubMed ID: 30348169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth.
    Della Monica R; Buonaiuto M; Cuomo M; Pagano C; Trio F; Costabile D; de Riso G; Cicala FS; Raia M; Franca RA; Del Basso De Caro M; Sorrentino D; Navarra G; Coppola L; Tripodi L; Pastore L; Hench J; Frank S; Schonauer C; Catapano G; Bifulco M; Chiariotti L; Visconti R
    Cell Death Dis; 2023 Sep; 14(9):638. PubMed ID: 37758718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
    Patani N; Jiang WG; Newbold RF; Mokbel K
    Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
    Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
    Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Netrin signaling mediates survival of dormant epithelial ovarian cancer cells.
    Perampalam P; MacDonald JI; Zakirova K; Passos DT; Wasif S; Ramos-Valdes Y; Hervieu M; Mehlen P; Rottapel R; Gibert B; Correa RJM; Shepherd TG; Dick FA
    Elife; 2024 Jul; 12():. PubMed ID: 39023520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HMGA2 gene is a promising target for ovarian cancer silencing therapy.
    Malek A; Bakhidze E; Noske A; Sers C; Aigner A; Schäfer R; Tchernitsa O
    Int J Cancer; 2008 Jul; 123(2):348-356. PubMed ID: 18452175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
    Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
    J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circular RNA profiling reveals circRNA1656 as a novel biomarker in high grade serous ovarian cancer.
    Gao Y; Zhang C; Liu Y; Wang M
    Biosci Trends; 2019 May; 13(2):204-211. PubMed ID: 31019161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SETD8 inhibition targets cancer cells with increased rates of ribosome biogenesis.
    Murga M; Lopez-Pernas G; Soliva R; Fueyo-Marcos E; Amor C; Faustino I; Serna M; Serrano AG; Díaz L; Martínez S; Blanco-Aparicio C; Antón ME; Seashore-Ludlow B; Pastor J; Jafari R; Lafarga M; Llorca O; Orozco M; Fernández-Capetillo O
    Cell Death Dis; 2024 Sep; 15(9):694. PubMed ID: 39341827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.
    Kohler RS; Anugraham M; López MN; Xiao C; Schoetzau A; Hettich T; Schlotterbeck G; Fedier A; Jacob F; Heinzelmann-Schwarz V
    Oncotarget; 2016 Aug; 7(32):51674-51686. PubMed ID: 27429195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
    Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
    J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
    Luo X; Cao J; Zhang C; Huang H; Liu J
    Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.